title: Dermatologic manifestations of Crohn disease in children: response to infliximab.
abstract: Dermatologic extraintestinal manifestations of Crohn disease may be refractory to treatment with corticosteroids and immunomodulators. The authors describe four children with Crohn disease with dermatologic manifestations: pyoderma gangrenosum, orofacial involvement, erythema nodosum, and idiopathic lymphedema. These dermatologic conditions were unresponsive to conventional therapy but had rapid and sustained response to the anti-TNF-alpha antibody infliximab. No adverse reactions occurred. Infliximab should be considered for treating the extraintestinal dermatologic manifestations of Crohn disease in children.
authors.affiliation: Division of Pediatric Gastroenterology and Nutrition, Children's Hospital of Wisconsin, Milwaukee, Wisconsin 53226, USA. skuga@mcw.edu
authors.forename: Subra
authors.initials: S
authors.lastname: Kugathasan
authors.forename: Adrian
authors.initials: A
authors.lastname: Miranda
authors.forename: James
authors.initials: J
authors.lastname: Nocton
authors.forename: Beth A
authors.initials: BA
authors.lastname: Drolet
authors.forename: Carolyn
authors.initials: C
authors.lastname: Raasch
authors.forename: David G
authors.initials: DG
authors.lastname: Binion
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003424:Crohn Disease / Q000150:complications*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004893:Erythema Nodosum / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D000069285:Infliximab; D008209:Lymphedema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab